- 24/11/2020 - 30/5/2022
- Drugs for Neglected Diseases initiative (DNDi)
- German Federal Ministry of Education and Research (BMBF) through a credit for reconstruction (KfW) and the global health agency Unitaid, as part of ACT-A
The aim of the ANTICOV clinical trial is to respond to the urgent need to identify treatments that can be used in the early treatment of mild to moderate cases of COVID-19 to prevent hospitalisation surges that could overwhelm fragile and overburdened health systems in Africa.
The clinical trial will be carried out at 19 sites in 13 African countries by the ANTICOV consortium, which includes 26 African organisations and well-known international research and development institutions, including ISGlobal. The project is being coordinated by the Drugs for Neglected Diseases initiative.
ANTICOV will assess the safety and efficacy of different treatments in 2000 to 3000 patients with mild to moderate disease who have not been hospitalised. Trials will take place in Burkina Faso, Cameroon, Côte d’Ivoire, Ethiopia, Ghana, Guinea, Equatorial Guinea, Kenya, Mali, Mozambique, the Democratic Republic of Congo (DRC), Sudan and Uganda. The aim is to ascertain whether early treatment can prevent progression of COVID-19 to severe disease and potentially limit transmission.
ISGlobal’s role in the ANTICOV project is twofold. First, the Institute will work together with two of the hospitals where clinical trials are being carried out, both located in Mozambique: the Manhiça Health Research Centre (CISM) and the Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC), which forms part of the country’s National Institute of Health.
In addition, ISGlobal is co-leader, together with the Institute of Tropical Medicine (ITM) in Antwerp (Belgium), of one of the project’s two ancillary studies. This is an immunology study that will be carried out in 7 countries to analyse whether the treatments tested in the clinical trial in patients with mild to moderate COVID-19 alter the strength or duration of immune responses to SARS-CoV-2. The researchers will study antibodies and T-lymphocytes and compare the immune responses of symptomatic and asymptomatic patients
- Denise Suzanne Naniche Directora científica
Co-PI and Technical coordinator
- Elisa Blanca López Medical Research Fellow
Scientific Leader of the IMMUNO study and Co-PI of the IMMUNO Study
- Gemma Moncunill Assistant Research Professor
Altres projectesVeure projectes passats
Integrating and decentralizing diabetes and hypertension services in Africa
Combatent la Resistència Bacteriana a Europa
Eradicació del Pian
Application to medical devices
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Prioritising Antimicrobial Resistance: establishing an interdisciplinary International Research Partnership to tackle an evolving global health threat
An interdisciplinary International Research Partnership to tackle an evolving global health threat
Development of new metal-antibiotics against pathogens causing chronic infections in patients with cystic fibrosis.
New metal-antibiotics for patients with cystic fibrosis
Non-invasive ultrasound-based screening for meningitis: Proof-of concept in infants
Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique
Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals
Search for new target proteins and use of antibacterial or inhibitory peptides against resistance mechanisms in 'Acinetobacter baumannii'
Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique
Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.
Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo
Estudio piloto para evaluar el potencial de la ivermectina para reducir la transmisión de COVID-19
Cendea de Cizur
Conèixer la propagació. Entendre la protecció
A breakthrough device for the rapid detection of antimicrobial resistance
Hepatitis B Virus COMmunity Screening and Vaccination in Africans
Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV